Investor Presentaiton

Hematology Reblozyl BET Inhibitor Breyanzi golcadomide Abecma alnuctamab GPRC5D iber/mezi Moving into earlier lines of therapy in multiple myeloma Today Abecma (idecabtagene vicleucel) SUSPENSION FOR IV INFUSION 5L+ MM with differentiated real-world evidence Near-Term Moving into a triple-class exposed population KarMMa-3 is currently under review in U.S., EU, and Japan Future Phase 3, KarMMa-9 study initiating Expansion to NDMM with inadequate response to transplant Ill Bristol Myers Squibb™ Not for Product Promotional Use 81

View entire presentation